Please use this identifier to cite or link to this item:
|Title:||The Possible Impact of Human Embryonic Stem Cells on Safety Pharmacological and Toxicological Assessments in Drug Discovery and Drug Development|
|Authors:||STUMMANN TINA; BREMER SUSANNE|
|Citation:||Current Stem Cell Research & Therapy vol. 3 no. 2 p. 117-130|
|Publisher:||Bentham Science Publishers|
|JRC Publication N°:||JRC37811|
|Type:||Articles in Journals|
|Abstract:||The successful establishment of human embryonic stem cell (hESC) lines has raised high expectation for their future applications. The major focus of hESC research has been on their potential use in replacement therapies. However, the most immediate application of hESCs may be in establishment of humanised in vitro tests, which have potential to reduce problems of interspecies variations in safety assessments. Improved prediction of human hazard would increase patient safety and reduce the number of laboratory animals needed for toxicological and safety pharmacological testing, leading to improved efficiency of drug discovery and development in term of cost and time. The current review describes some of the newest research programmes on the use of hESCs for safety evaluations of conventional drugs. It provides an overview of the possible impact of hESCs and their derivates on regulatory drug safety assessments and discusses the potential effects on the product pipeline organisation. The review additionally summarizes initiatives in establishing quality criteria for hESC expansion and differentiation. Such criteria are necessary in order to achieve high standardisation and throughput of pharmacological and toxicological tests. Finally, it will discuss the actions needed to scientifically prove the relevance and reliability of safety tests based on hESCs.|
|JRC Institute:||Institute for Health and Consumer Protection|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.